Clinical experience with amikacin, a new aminoglycoside antibiotic.
Amikacin, a new semisynthetic aminoglycoside antibiotic, was administered parenterally to 20 patients suffering from severe Gram-negative bacterial infections. The antibiotic was found to be highly effective in controlling infection. It was well tolerated and no signs of nephro- or otoxicity were observed. The few side-effects which were seen appeared to be dose-related. The recommended 12-hourly dosage regimen has also proved useful in medium- to long-term management of refractory pulmonary infections.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000583:Amikacin / Q000009:adverse effects / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D007710:Klebsiella Infections / Q000188:drug therapy; D007711:Klebsiella pneumoniae; D008171:Lung Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy
D007612:Kanamycin; D000583:Amikacin